Kyverna Therapeutics rugi bersih Q2 FY26 menyempit jadi USD 38,32 juta

Reuters2026/08/11 20:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kyverna Therapeutics membukukan rugi bersih 2Q 2026 sebesar USD 38,32 juta, menyempit dari USD 42,08 juta setahun sebelumnya.
Rugi per saham turun menjadi USD 0,63 dari USD 0,97 pada periode yang sama tahun lalu.
Beban R&D merosot 30,79% menjadi USD 24,79 juta, sementara beban umum dan administrasi naik 71,82% menjadi USD 14,77 juta.
Kas, setara kas, dan surat berharga per 30 Juni 2026 turun menjadi USD 199,43 juta dari USD 279,25 juta pada 31 Desember 2025.
Kyverna menargetkan penyelesaian pengajuan BLA bergulir miv-cel untuk stiff person syndrome pada 4Q 2026, dengan potensi peluncuran komersial 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608111602PRIMZONEFULLFEED9807795) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kyverna Therapeutics rugi bersih Q2 FY26 menyempit jadi USD 38,32 juta

You may also like

Crypto prices